VV-GMCSF-Lact / Oncostar - LARVOL DELTA

Efficacy of Oncolytic Virus VV-GMCSF-Lact Against Immunocompetent Glioma. (PubMed, Cells) - "Results of the study allowed us to determine the viral dose that does not lead to toxic effects and can potentially increase life expectancy of mice. The data obtained show the need for careful selection of both the route of viral drug dose and administration."

IO biomarker • Journal • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor • Transplantation • CSF2

Single-Cell Transcriptomic Changes in Patient-Derived Glioma and U87 Glioblastoma Cell Cultures Infected with the Oncolytic Virus VV-GMCSF-Lact. (PubMed, Int J Mol Sci) - "Furthermore, higher viral loads were accompanied by a large-scale downregulation of genes involved in mitochondrial translation, metabolism, and oxidative phosphorylation. Levels of early vaccinia virus transcripts are also positively correlated with infection intensity, suggesting that the fate of cells is determined at the early stage of infection."

IO biomarker • Journal • Preclinical • Brain Cancer • Glioblastoma • Glioma • Infectious Disease • Oncology • Solid Tumor • CSF2

Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact (clinicaltrials.gov) - P1 | N=34 | Completed | Sponsor: "Oncostar" LLC | Recruiting ➔ Completed | N=73 ➔ 34 | Trial completion date: May 2024 ➔ Feb 2025 | Trial primary completion date: Jul 2023 ➔ Feb 2025

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor

Using Computer Modeling and Experimental Methods to Screen for Aptamers That Bind to the VV-GMCSF-LACT Virus. (PubMed, Molecules) - "Aptamers that specifically bind to the JX-594 strain of the vaccinia virus were developed earlier. The synergistic effect of the VV-GMCSF-Lact combination with the aptamers in the presence of serum was investigated using human glioblastoma cells. This proposed approach allowed us to conduct a preliminary screening of sequences using in silico modeling and experimental methods, and identified potential candidates that are capable of shielding VV-GMCSF-Lact from virus-neutralizing antibodies."

Journal • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • CSF2

The Recombinant Oncolytic Virus VV-GMCSF-Lact and Chemotherapy Drugs against Human Glioma. (PubMed, Int J Mol Sci) - "Testing these regimens in the U87 MG xenograft glioblastoma model confirmed this effect, as assessed by tumor growth inhibition index and histological analysis. Moreover, VV-GMCSF-Lact as monotherapy is more effective against U87 MG glioblastoma xenografts comparing temozolomide."

Journal • Oncolytic virus • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor • CSF2

Characterizing Aptamer Interaction with the Oncolytic Virus VV-GMCSF-Lact. (PubMed, Molecules) - "Thus, NV14t_56 has the ability to inhibit virus aggregation, allowing VV-GMCSF-Lact to maintain its effectiveness throughout the storage period and subsequent use. When employing aptamers as protective agents for oncolytic viruses, the presence of neutralizing antibodies should be taken into account."

Journal • Oncolytic virus • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor • CSF2

Transcriptome Changes in Glioma Cells upon Infection with the Oncolytic Virus VV-GMCSF-Lact. (PubMed, Cells) - "Genes whose expression correlates with the sensitivity of cells to the virus are important for increasing the effectiveness of cancer virotherapy. Overall, the results highlight molecular markers, biological pathways, and gene networks influencing the response of glioma cells to VV-GMCSF-Lact."

IO biomarker • Journal • Oncolytic virus • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Infectious Disease • Oncology • Solid Tumor • CSF2 • IFNG

The Signaling Pathways Controlling the Efficacy of Glioblastoma Therapy. (PubMed, Acta Naturae) - "Hence, we suggest that the sensitivity of glioblastoma cells to the oncotoxic effect of VV-GMCSF-Lact is determined by the nature and extent of the disturbances in cell death regulation in various cultures. Further investigation of the factors affecting glioblastoma resistance to virotherapy will test this hypothesis and identify targets for antitumor therapy, combined with VV-GMCSF-Lact."

Journal • Brain Cancer • Glioblastoma • Infectious Disease • Oncology • Solid Tumor • CSF2

Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact (clinicaltrials.gov) - P1 | N=73 | Recruiting | Sponsor: "Oncostar" LLC

New P1 trial • Breast Cancer • Oncology • Solid Tumor